Document is current

Article History

Received: 16 April 2024

Accepted: 20 December 2024

First Online: 8 January 2025

Declarations

:

: This study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practices and the Declaration of Helsinki 2008 and approved by the Ethics Committee at the City Clinical Hospital No 52 of the Department of Healthcare of Moscow for the Moscow Rheumatology Centre site, the Ethics Committee at the North-West State Medical University named after I.I. Mechnikov of the Ministry of Health of the Russian Federation for the North-western State Medical University named after I.I. Mechnikov site, the Ethics Committee at the Ulyanovsk Regional Clinical Hospital for the Ulyanovsk Regional Clinical Hospital site, and the Ethics Committee at the Research Institute of Rheumatology named after V.A. Nasonova for the Research Institute of Rheumatology site. The requirement for patient informed consent was waived by the corresponding Ethics Committees listed above for each involved center as the study was non-interventional, and patient data were de-identified.

: Not applicable.

: AML, EAA, AIZ, IBV, and RRS have received grants from GSK during the conduct of the study. MK, LT, JQ, and SN are employees of GSK. DdS and TE were employees of GSK at the time of the study. MK, TE, and SN hold financial equities in GSK. LAK is a former employee of GSK and a current employee of No. 1 Medical Center, Department of Rheumatology, Kursk, Russian Federation.